DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin
Authors:
Open Access
- 1 August 2017
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 400, 194-202
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81401979, 81402944, 81572604)
- the Science and Technology Department of Sichuan Province Foundation (2014SZ0020)
- China Postdoctoral Science Foundation (2014M552367)
This publication has 46 references indexed in Scilit:
- Challenges in molecular testing in non-small-cell lung cancer patients with advanced diseaseThe Lancet, 2016
- A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesOncotarget, 2015
- Refining the treatment of NSCLC according to histological and molecular subtypesNature Reviews Clinical Oncology, 2015
- Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinibOncogene, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsCancer Treatment Reviews, 2014
- Acquired resistance to TKIs in solid tumours: learning from lung cancerNature Reviews Clinical Oncology, 2014
- Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcomeCancer Treatment Reviews, 2014
- Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Chemotherapy, chemoresistance and the changing treatment landscape for NSCLCLung Cancer, 2011